SIGA Technologies (SIGA) & Trillium Therapeutics (TRIL) Financial Comparison

SIGA Technologies (NASDAQ: SIGA) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for SIGA Technologies and Trillium Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SIGA Technologies 0 0 0 0 N/A
Trillium Therapeutics 0 0 3 0 3.00

Trillium Therapeutics has a consensus target price of $12.50, suggesting a potential upside of 38.12%. Given Trillium Therapeutics’ higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than SIGA Technologies.

Valuation and Earnings

This table compares SIGA Technologies and Trillium Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
SIGA Technologies N/A N/A N/A ($0.53) -9.21
Trillium Therapeutics N/A N/A -$23.96 million ($3.73) -2.43

SIGA Technologies is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SIGA Technologies and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies -175.90% N/A -18.99%
Trillium Therapeutics N/A -178.08% -61.40%

Volatility and Risk

SIGA Technologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of Trillium Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Trillium Therapeutics beats SIGA Technologies on 5 of the 8 factors compared between the two stocks.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

What are top analysts saying about SIGA Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SIGA Technologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit